Gastrointestinal

Colon polyps: surveillance intervals by histology

Clinical Overview and When to Suspect Recurrent Neoplasia After Polypectomy

— Adenomas (tubular, tubulovillous, villous)

— Sessile serrated lesions (SSL) or traditional serrated adenomas (TSA)

— Large (≥10 mm) or numerous (≥3) polyps

— HGD on any polyp histology

— Piecemeal EMR of large (≥20 mm) lesions

Board pearl: Step 3 stems will plant a quality-of-exam clue (e.g., "Boston Bowel Prep Scale 4," "piecemeal resection," "unable to retrieve specimen"). The right answer is often repeat colonoscopy within 1 year or sooner, not the histology-based interval.

Step 3 management: Always anchor surveillance on the most recent colonoscopy results, not the original screening exam. Reset the clock at each high-quality exam. Document family history, since a first-degree relative with CRC <60 or 2 FDRs at any age moves the patient to a high-risk screening pathway that overrides routine post-polypectomy intervals.

Why surveillance matters: Colorectal cancer (CRC) is the 2nd-leading cause of cancer death in the US. ~85–90% arise from adenomatous or serrated precursors. Removing polyps and performing risk-stratified surveillance reduces CRC incidence and mortality.

Goal of post-polypectomy surveillance: detect metachronous advanced neoplasia (adenoma ≥10 mm, villous/tubulovillous histology, high-grade dysplasia [HGD], or CRC) before invasive cancer develops. Intervals are set by the index colonoscopy findings, assuming a high-quality complete exam with adequate prep and complete polyp resection.

Who needs an interval shorter than screening? Patients with:

Who returns to average-risk screening (10 years)? Normal colonoscopy, or 1–2 small (<10 mm) tubular adenomas with low-grade dysplasia, or ≤20 small hyperplastic polyps in the rectosigmoid.

Suspect inadequate index exam when prep was fair/poor, cecal intubation not documented, withdrawal time <6 min, or polyp resection was piecemeal/incomplete — these mandate early repeat rather than standard intervals.

Presentation Patterns and Key History

— Number of adenomas removed (1–2 vs 3–4 vs 5–10 vs >10)

— Size of the largest polyp (<10 mm vs ≥10 mm)

— Histology: tubular vs tubulovillous/villous; low-grade vs high-grade dysplasia; serrated subtype

— Completeness of resection (en bloc vs piecemeal, especially for lesions ≥20 mm)

— Quality of prep (adequate = Boston ≥6 total with each segment ≥2)

— Family history of CRC or advanced adenoma in a first-degree relative

— Hematochezia, melena, iron-deficiency anemia in a man or postmenopausal woman

— Unexplained weight loss, change in bowel caliber

— New iron deficiency at any age once menstrual loss is excluded

— ≥10 cumulative adenomas → consider FAP/MUTYH-associated polyposis, refer for genetic testing

— ≥5 serrated polyps proximal to rectum (≥2 ≥10 mm) or ≥20 serrated polyps any size → serrated polyposis syndrome

— CRC <50, Lynch-pattern family history, or tumor with MSI-H/MMR loss → Lynch syndrome

Key distinction: A patient with rectal bleeding 6 months after polypectomy needs a diagnostic colonoscopy now, not their scheduled 3-year surveillance. Surveillance intervals assume an asymptomatic patient; new symptoms reset the workup.

Board pearl: When the stem lists "5 adenomas, one was 12 mm with high-grade dysplasia," count each risk feature separately — multiplicity (3–4 or 5–10), size ≥10 mm, and HGD all independently shorten the interval. The shortest applicable interval wins.

Most polyps are asymptomatic and discovered on screening colonoscopy. Step 3 vignettes typically present the patient after polypectomy, asking when to bring them back.

History elements that change the surveillance interval:

Symptomatic presentations that should prompt diagnostic, not surveillance, colonoscopy:

Red-flag history suggesting a hereditary syndrome (manage differently from sporadic polyps):

Physical Exam Findings and Endoscopic Assessment

— Location: right colon serrated lesions carry higher risk of interval cancer via the CIMP/BRAF pathway

— Morphology (Paris classification): pedunculated (Ip), sessile (Is), flat (IIa), depressed (IIc) — depressed lesions have higher malignancy risk

— Size measured with open biopsy forceps (not estimated)

— Resection technique: cold snare, hot snare, EMR, ESD; en bloc vs piecemeal

— Completeness: visual inspection of margins, ± submucosal tattoo for follow-up site

— Palpable abdominal mass, hepatomegaly, or lymphadenopathy → suspect CRC, not just polyp

— Digital rectal exam revealing a mass → biopsy + staging workup

— Pallor / orthostasis from chronic GI loss → workup for occult bleeding

— Osteomas, epidermoid cysts, desmoids, congenital hypertrophy of retinal pigment epithelium → Gardner/FAP variant

— Mucocutaneous pigmentation on lips/buccal mucosa → Peutz-Jeghers

— Trichilemmomas, macrocephaly → Cowden (PTEN hamartoma)

CCS pearl: On a CCS case where polyps are found, order "colonoscopy report" and "pathology report" as separate items — the surveillance interval depends on histology that arrives 3–7 days later. Don't schedule the follow-up before the path returns.

Step 3 management: If the endoscopist reports a large sessile polyp resected piecemeal, the next step is a first surveillance colonoscopy at 6 months to inspect and re-treat the scar, regardless of histology — this overrides standard intervals because residual neoplasia rates exceed 15%.

General physical exam is usually unremarkable in patients with polyps. The "exam" in Step 3 stems is really the endoscopic and pathologic description.

Endoscopic features documented at colonoscopy that drive surveillance:

Findings on exam that change the plan:

Skin and extraintestinal exam clues to polyposis syndromes:

Diagnostic Workup — Index Colonoscopy and Pathology

— Adequate bowel prep (Boston Bowel Prep Scale ≥6 total, each segment ≥2; or "adequate to detect polyps >5 mm")

— Cecal intubation with photo documentation of appendiceal orifice/ileocecal valve

— Withdrawal time ≥6 minutes in a normal colon

— Adenoma detection rate of the endoscopist (≥25% overall; ≥30% men, ≥20% women)

— Histologic type: tubular adenoma, tubulovillous (≥25% villous), villous (>75% villous), sessile serrated lesion (with or without dysplasia), traditional serrated adenoma, hyperplastic polyp

— Dysplasia grade: low-grade (LGD) vs high-grade (HGD)

— Invasive component: intramucosal carcinoma vs submucosal invasion (T1) — the latter exits the surveillance pathway into CRC management

— Symptoms (anemia, bleeding) → CBC, iron studies

— Suspicion of malignancy in resected specimen → CT chest/abdomen/pelvis, CEA, multidisciplinary referral

— Hereditary syndrome suspected → germline genetic testing after counseling

Board pearl: If pathology shows adenocarcinoma invading the submucosa (T1) in a polypectomy specimen, evaluate for high-risk features: poor differentiation, lymphovascular invasion, positive margin (<1 mm), or tumor budding. Any of these → refer for surgical resection, not surveillance colonoscopy.

Step 3 management: Always confirm complete resection in the endoscopy note before assigning an interval. "Polyp not retrieved" is treated as adenoma for surveillance purposes (assume worst case).

High-quality index colonoscopy is the foundation of any surveillance plan. Required documentation:

Pathology elements that determine the interval:

Adjunct labs/imaging are not routine after polypectomy. Order only if:

FIT or stool DNA tests are not used for surveillance after polypectomy — they are screening tests for average-risk patients. Substituting FIT for surveillance colonoscopy is a wrong answer on Step 3.

Diagnostic Workup — Confirming Histology and Special Studies

— Hyperplastic polyps (<10 mm, rectosigmoid, ≤20 in number): no increased CRC risk → return to 10-year screening

— Tubular adenoma: the most common; risk scales with number and size

— Tubulovillous/villous adenoma: advanced histology regardless of size

— Sessile serrated lesion (SSL): flat, right-sided, BRAF-mutated; precursor to ~15–20% of CRC

— SSL with dysplasia or traditional serrated adenoma (TSA): higher risk, shorter interval

— HGD in any adenoma: advanced lesion, 3-year interval

— CRC <50 or family history suggests Lynch → MMR IHC ± MSI testing on tumor; if abnormal, germline testing

— ≥10 cumulative adenomas → APC, MUTYH germline testing

— Serrated polyposis criteria met → consider RNF43 and refer to genetics

— Prep was inadequate → repeat within 1 year (often <6 months if poor)

— Piecemeal resection of lesion ≥20 mm → repeat at 6 months

— Incomplete colonoscopy (failed cecal intubation) → CT colonography or repeat colonoscopy

Key distinction: Villous histology and high-grade dysplasia are independent features of an "advanced adenoma," along with size ≥10 mm. Any single feature qualifies — they don't have to coexist. Three small tubular adenomas with LGD is not advanced histology, but three adenomas still shortens the interval based on number.

Board pearl: A 7-mm rectal hyperplastic polyp does not shorten screening — patient still returns in 10 years. Don't be tricked by the word "polyp."

Pathology review is the confirmatory study for polyp surveillance. Step 3 expects you to read a path report and assign an interval.

Key histologic categories and their surveillance implications:

Molecular/genetic studies (not routine, but ordered when):

Repeat colonoscopy as a "diagnostic" rather than surveillance study is indicated when:

Risk Stratification — Surveillance Intervals by Histology (Core Table)

Board pearl: When multiple features apply, the shortest interval wins. Example: 5 adenomas including one 12-mm tubulovillous with HGD → multiple features each say 3 years → answer is 3 years.

Step 3 management: Always confirm the next-interval reset rule: if the 3-year surveillance shows only 1–2 small tubular adenomas with LGD, you extend back out — the next interval can be 5 years, not back to 10. Recurrence at any future exam shortens again per the table.

Key distinction: "Advanced adenoma" = ≥10 mm OR villous OR HGD. "Advanced serrated lesion" = SSL ≥10 mm OR SSL with dysplasia OR TSA. Both pathways converge on a 3-year interval.

2020 US Multi-Society Task Force (USMSTF) recommendations — memorize this for Step 3:

Normal colonoscopy → 10 years

1–2 small (<10 mm) tubular adenomas with LGD → 7–10 years

3–4 small tubular adenomas with LGD → 3–5 years

5–10 small tubular adenomas with LGD → 3 years

Adenoma ≥10 mm → 3 years

Adenoma with tubulovillous/villous histology → 3 years

Adenoma with high-grade dysplasia → 3 years

>10 adenomas on single exam → 1 year (and consider polyposis syndrome workup)

Piecemeal resection of adenoma or SSL ≥20 mm → 6 months to evaluate scar

Hyperplastic polyps <10 mm in rectosigmoid (any number ≤20) → 10 years

Hyperplastic polyp ≥10 mm → 3–5 years

Sessile serrated lesion <10 mm, no dysplasia, 1–2 in number → 5–10 years

SSL <10 mm, 3–4 in number → 3–5 years

SSL <10 mm, 5–10 in number → 3 years

SSL ≥10 mm, or SSL with dysplasia, or traditional serrated adenoma → 3 years

Serrated polyposis syndrome (per WHO criteria) → 1 year

Pharmacotherapy and Chemoprevention Considerations

— USPSTF (2022 update): individualized decision for adults 40–59 with ≥10% 10-year CVD risk; do not initiate for primary prevention ≥60 due to bleeding risk

— Aspirin reduces CRC incidence after ~10 years of use, but is not prescribed solely for CRC prevention outside Lynch syndrome

— Lynch syndrome: daily aspirin (typically 600 mg in CAPP2; lower doses also studied) reduces CRC risk — discuss with patient

— Low-risk procedure (diagnostic ± biopsy): continue aspirin; usually continue DOACs

— High-risk (polypectomy, especially ≥10 mm or EMR): hold DOAC 48 h prior (longer if CrCl <50); hold warfarin 5 days with bridging only if mechanical mitral valve, recent VTE, or high-risk AF

— Continue aspirin through polypectomy in most cases; clopidogrel held 5–7 days if cardiology approves

— Resume anticoagulation 24–48 h post-procedure based on bleeding risk

Step 3 management: A patient on apixaban for nonvalvular AF undergoing surveillance colonoscopy with planned polypectomy → hold apixaban 48 hours pre-procedure, no bridging needed, resume the evening of the procedure if hemostasis achieved.

Board pearl: Don't recommend aspirin solely for CRC prevention on a Step 3 stem unless the patient has Lynch syndrome — pick the answer that addresses CVD risk instead.

No pharmacotherapy replaces surveillance colonoscopy. However, several agents reduce metachronous adenoma risk and may appear in Step 3 stems:

Aspirin:

NSAIDs (sulindac, celecoxib): reduce adenoma burden in FAP but cause CV/GI toxicity; used adjunctively, not as a substitute for colectomy timing

Calcium and vitamin D: modest reduction in adenoma recurrence in some trials; not a guideline-recommended chemoprevention strategy

Hormone therapy: reduces CRC risk in postmenopausal women but not recommended for CRC prevention due to other risks

Statins, metformin, fiber, folate: insufficient evidence to recommend for CRC chemoprevention

Antiplatelet/anticoagulant management around surveillance colonoscopy:

Procedures — Polypectomy Technique and Post-Procedure Surveillance

— Diminutive polyps (<5 mm): cold snare or cold forceps; en bloc resection straightforward

— Small polyps (6–9 mm): cold snare polypectomy is preferred — lower delayed bleeding, complete resection ≥95%

— Sessile polyps 10–19 mm: cold snare for SSLs; hot snare or EMR for adenomas

— Lesions ≥20 mm: endoscopic mucosal resection (EMR) by an expert; often piecemeal

— Deeply invasive or non-lifting lesions: consider ESD or surgical resection

— Recurrence rate 10–20% even with expert technique

— First surveillance at 6 months to inspect scar, biopsy/re-treat residual tissue

— Second surveillance at 1 year from index, then 3 years if clear

— Tattoo placement adjacent to (not on) the resection site for relocalization

— Post-polypectomy bleeding: 1–2% overall, up to 6% for large lesions; immediate or delayed up to 14 days

— Perforation: ~0.1% diagnostic, up to 1% with EMR/ESD

— Post-polypectomy electrocoagulation syndrome: fever, focal peritonitis, leukocytosis without free air — manage with bowel rest, antibiotics, observation

— Polyp not endoscopically resectable (size, location, fibrosis)

— Invasive cancer with high-risk features on polypectomy specimen

— Hereditary polyposis syndromes meeting colectomy criteria

CCS pearl: After EMR of a 25-mm right colon SSL, order: pathology, return precautions for bleeding, clear liquids advancing to regular diet, hold anticoagulants per plan, and schedule surveillance colonoscopy at 6 months. Don't default to 3 years.

Board pearl: Cold snare polypectomy is now first-line for nonpedunculated polyps <10 mm — lower bleeding, no electrocautery injury, equivalent completeness.

Resection technique determines surveillance interval when lesions are large:

Piecemeal EMR of lesions ≥20 mm:

Complications to discuss for informed consent:

Surgical referral indications:

Special Populations — Elderly and Renal/Hepatic Impairment

— Screening colonoscopy: USPSTF recommends through age 75, individualized 76–85, generally not after 85

— Surveillance: continue as long as life expectancy >10 years and patient is fit for colonoscopy and any needed intervention

— Age >75–80 with multiple comorbidities

— Frailty, dementia, advanced CHF/COPD/CKD

— Prior surveillance exams negative or showing only small low-risk lesions

— Patient preference after informed discussion

— Prior advanced adenoma, large piecemeal EMR site, or HGD

— Good functional status, life expectancy >10 years

— Lynch syndrome or other hereditary risk

— Bowel prep choice: avoid sodium phosphate preps (acute phosphate nephropathy) in CKD, elderly, ACE/ARB/diuretic users — use polyethylene glycol (PEG)-based preps

— Sedation: propofol dose reduction; avoid meperidine if CrCl <30

— DOAC dosing: apixaban/rivaroxaban require longer hold times if CrCl <50 mL/min (hold 72 h)

— Cirrhosis increases procedural bleeding risk; correct coagulopathy and thrombocytopenia as needed

— Variceal screening colonoscopy is not a thing — but colonoscopy in cirrhotics requires platelet support if <50K and consideration of TIPS-related anatomy

Step 3 management: An 82-year-old with mild HTN, intact ADLs, and a prior 15-mm tubulovillous adenoma at age 78 is due for 3-year surveillance. Life expectancy >10 years and prior advanced lesion → proceed with surveillance, then likely stop after this exam if clear.

Board pearl: "Patient has metastatic pancreatic cancer and is due for adenoma surveillance" → defer/cancel surveillance. Surveillance only benefits patients who would benefit from finding and treating future neoplasia.

Surveillance has a stopping age, unlike screening's hard cutoff:

Factors that argue for stopping surveillance:

Factors that argue for continuing past 75:

Renal impairment considerations:

Hepatic impairment:

Special Populations — IBD, Family History, and Hereditary Syndromes

— Begin 8–10 years after symptom onset (immediately if PSC)

— Chromoendoscopy or high-definition WLE with targeted biopsies

— Interval 1–5 years based on dysplasia history, disease extent, severity, family history

— 1 FDR with CRC or advanced adenoma <60, or 2 FDRs at any age: start screening at age 40 or 10 years before youngest case, repeat every 5 years

— 1 FDR with CRC ≥60: start at 40, then standard 10-year interval

— After a polyp is found, surveillance follows the histology-based table, but the patient remains in a higher-risk family pathway

— Colonoscopy every 1–2 years starting at 20–25 (or 2–5 years before youngest case)

— Aspirin chemoprevention discussion

— Extra-colonic surveillance: endometrial, ovarian, urinary tract, gastric

— Annual sigmoidoscopy/colonoscopy starting at 10–15 (classic FAP) or 18–20 (attenuated)

— Prophylactic colectomy when polyp burden cannot be managed endoscopically

— Upper endoscopy starting at 20–25 for duodenal/ampullary surveillance

Key distinction: Pregnancy is not a contraindication to colonoscopy, but defer elective surveillance until postpartum. Urgent indications (significant bleeding, suspected cancer) can proceed in 2nd trimester with GI/OB coordination.

Board pearl: A 35-year-old with 30 adenomas on first colonoscopy is not a "5–10 year interval" patient — recognize this as polyposis syndrome, refer to genetics, and plan for colectomy timing, not surveillance colonoscopy.

Inflammatory bowel disease (IBD): post-polypectomy intervals do not apply. Patients with ulcerative colitis or Crohn colitis follow dysplasia surveillance:

Family history of CRC modifies the baseline screening start age, not the polypectomy interval:

Lynch syndrome (HNPCC):

Familial adenomatous polyposis (FAP):

MUTYH-associated polyposis: colonoscopy every 1–2 years starting at 25–30 for biallelic carriers

Serrated polyposis syndrome (WHO): colonoscopy every 1 year until polyps controlled

Complications and Adverse Outcomes of Surveillance

— Post-polypectomy bleeding: immediate (hemoclips, epinephrine injection, thermal therapy) or delayed (admit, transfuse if needed, repeat colonoscopy if hemodynamically significant)

— Perforation: present with abdominal pain, peritoneal signs, fever; CT confirms; small contained perforations may be managed conservatively with antibiotics and bowel rest, larger ones need surgery

— Post-polypectomy syndrome: abdominal pain, fever, leukocytosis without free air — full-thickness thermal injury without perforation; treated with IV fluids, antibiotics, bowel rest

— Splenic injury: rare, presents with LUQ pain, hypotension after colonoscopy

— Cardiopulmonary events related to sedation

— Procedural complications without benefit

— Increased cost, patient burden, anesthesia exposure

— Step 3 will sometimes test recognition of over-surveillance as a quality problem

— Interval cancer — CRC diagnosed between scheduled colonoscopies; right colon and serrated pathways disproportionately responsible

— Missed advanced adenoma progression

— Adenoma detection rate (ADR) — every 1% increase in ADR reduces interval CRC by ~3%

— Adequate withdrawal time, bowel prep, cecal intubation

— Use of high-definition scopes, water exchange technique

Step 3 management: Patient calls 6 days after polypectomy with bright red blood per rectum, BP 100/60, HR 105 → admit, IV access, type and screen, hold anticoagulants, gastroenterology consult for repeat colonoscopy with hemostasis.

Board pearl: Recurrent CRC at the prior polypectomy site within 3 years of "complete" piecemeal EMR is an expected event in 10–20% — this is why the 6-month scar check exists.

Procedural complications of surveillance colonoscopy:

Risks of over-surveillance (intervals shorter than indicated):

Risks of under-surveillance (intervals too long, or lost to follow-up):

Quality metrics that reduce interval cancer:

When to Escalate — Referrals and Multidisciplinary Care

— Large (≥20 mm) or complex polyps not amenable to standard polypectomy in a general practice setting

— Recurrent polyp at prior EMR site

— Serrated polyposis syndrome management

— Polyp not endoscopically resectable

— Invasive cancer in polypectomy specimen with high-risk features (poor differentiation, lymphovascular invasion, margin <1 mm, deep submucosal invasion ≥1000 µm, tumor budding)

— Polyposis syndrome with indication for colectomy

— ≥10 cumulative adenomas

— Serrated polyposis syndrome

— CRC <50 or polyp pathology suggesting Lynch (MMR-deficient adenoma)

— Strong family history meeting Amsterdam/Bethesda or Lynch criteria

— Confirmed invasive CRC, even T1 with high-risk features after definitive resection

— Staging and adjuvant therapy decisions

— Post-procedure peritonitis, ongoing bleeding requiring transfusion, or perforation → admit, surgical consult, NPO, broad-spectrum antibiotics

— Hemodynamic instability → ICU

CCS pearl: On CCS, the moment pathology shows "invasive adenocarcinoma in polyp specimen with lymphovascular invasion," your next orders are: CT chest/abdomen/pelvis with contrast, CEA, colorectal surgery consult, discuss in tumor board, and counsel patient on segmental colectomy. Do not order a 3-year surveillance colonoscopy.

Step 3 management: A 45-year-old with 12 adenomas → refer to genetics for APC/MUTYH testing, GI for short-interval (1-year) colonoscopy, and upper endoscopy to evaluate duodenal polyps if polyposis confirmed.

Board pearl: Don't conflate "complete polypectomy" with "cure of cancer." T1 lesions need surgical staging unless low-risk features and en bloc resection with clear margin.

Refer to GI for endoscopic management:

Refer to colorectal surgery:

Refer to genetics/genetic counseling:

Refer to oncology:

Inpatient escalation:

Key Differentials — Other Colonic Lesions That Mimic Adenomas

— Small, pale, often multiple in rectosigmoid

— No malignant potential when <10 mm and distal

— Do not shorten screening interval if ≤20 small distal lesions

— Flat, indistinct borders, often covered by mucus cap, right-sided

— Histology: dilated/branched crypts at base, "boot-shaped" crypts

— BRAF V600E mutation, CpG island methylator phenotype

— Precursor to ~15–20% of CRC via serrated pathway

— Less common, often left-sided, more clearly neoplastic histology

— Treated as advanced lesion → 3-year interval

— Seen in IBD, post-infectious colitis

— No malignant potential intrinsically; surveillance follows IBD protocol, not adenoma protocol

— Juvenile polyps: solitary in children usually benign; multiple → juvenile polyposis syndrome (SMAD4/BMPR1A)

— Peutz-Jeghers polyps: arborizing smooth muscle core, GI tract-wide, mucocutaneous pigmentation

— Cowden syndrome: PTEN mutation, multiple hamartomas, breast/thyroid cancer risk

Key distinction: A "polyp" on Step 3 isn't automatically an adenoma. Read the pathology line — hyperplastic distal polyps don't change surveillance, while SSLs absolutely do. Mistaking an SSL for a hyperplastic polyp is a common interval-cancer scenario.

Board pearl: Right-sided "hyperplastic-appearing" polyp ≥10 mm should be assumed to be a sessile serrated lesion until proven otherwise — assign a 3-year interval and ensure complete resection.

Hyperplastic polyps:

Sessile serrated lesions (SSL):

Traditional serrated adenomas (TSA):

Inflammatory pseudopolyps:

Hamartomatous polyps:

Lipomas, lymphoid aggregates, carcinoid tumors: submucosal lesions; biopsy/EUS for diagnosis, not standard polypectomy surveillance

Key Differentials — Non-Polyp Causes of Mucosal Lesions

— Rectal carcinoids most common in colon

— <1 cm without invasion: endoscopic resection with surveillance

— ≥2 cm or muscularis invasion: surgical resection

— Amebiasis (flask-shaped ulcers)

— CMV colitis in immunocompromised (deep ulcers)

— Schistosomiasis (polypoid lesions with eosinophilia)

Key distinction: Surveillance intervals apply only after a histologically confirmed adenomatous or serrated lesion has been completely resected. A "polyp" that turns out to be a carcinoid, GIST, or carcinoma follows its own management algorithm.

Step 3 management: Premenopausal woman with cyclic hematochezia and a "polyp" at the rectosigmoid → biopsy may show endometriosis; coordinate with gynecology, not 3-year surveillance.

Board pearl: Any rectal "polyp" with central ulceration, fixation, or friability in a patient with weight loss should be biopsied as a suspected cancer, not snared and sent home with a surveillance interval.

Colorectal adenocarcinoma: ulcerated, friable, often napkin-ring/apple-core on imaging; biopsy confirms; exits surveillance into staging and treatment

Neuroendocrine tumors (carcinoids):

GI stromal tumor (GIST): rare in colon, submucosal, KIT/PDGFRA-driven; managed surgically ± imatinib

Lymphoma: MALT or DLBCL involving colon; bulky, infiltrative; biopsy and oncology referral

Endometriosis: premenopausal woman, cyclical rectal bleeding, submucosal nodule; gynecology and colorectal coordination

Infectious lesions:

Ischemic colitis: segmental mucosal injury, often watershed (splenic flexure); polypoid regeneration tissue can mimic polyps

Radiation proctitis: telangiectasias and friable mucosa, history of pelvic radiation

Solitary rectal ulcer syndrome: young patient with straining, anterior rectal ulcer/polypoid lesion

Secondary Prevention and Long-Term Care Plan

— Tobacco cessation: smoking increases adenoma recurrence and CRC risk; offer counseling + pharmacotherapy

— Alcohol moderation: ≤1 drink/day women, ≤2 men; heavy use raises CRC risk

— Weight management: obesity is an independent CRC risk factor

— Physical activity: ≥150 min/week moderate intensity reduces CRC incidence

— Diet: higher fiber, fruits, vegetables, whole grains; limit processed and red meat

— Routine: not recommended solely for CRC prevention

— Lynch syndrome: discuss daily aspirin

— When already taking for CVD: continuation reduces CRC over time

— Document interval clearly in problem list and patient portal

— Generate automated recall reminder in EHR to avoid lapse

— Re-verify family history at each visit — new diagnoses may upgrade risk pathway

— Symptoms that warrant earlier evaluation: rectal bleeding, persistent change in bowel habits, unintentional weight loss, new iron deficiency

— Importance of completing bowel prep adequately at next exam

Step 3 management: After a 3-year-interval-qualifying exam, document in the after-visit summary: next colonoscopy date, rationale (e.g., one 12-mm tubulovillous adenoma), bowel prep instructions, and red-flag symptoms that should prompt earlier contact.

Board pearl: Lifestyle counseling appears on Step 3 because it's high-yield and frequently the "best next step" when the surveillance plan is already set — don't overlook it as an answer choice.

Lifestyle counseling at every post-polypectomy visit:

Aspirin for CRC chemoprevention:

Calcium/vitamin D supplementation: ensure adequacy but not specifically for chemoprevention

Diabetes control: insulin resistance and hyperinsulinemia associated with adenoma recurrence; optimize HbA1c and consider metformin (also associated with reduced CRC)

Continuity of care:

Patient education:

Follow-Up, Monitoring, and Quality Tracking

— Primary care typically owns the recall and referral

— GI documents the index findings and recommended interval

— Many systems use EHR-based registries that flag overdue surveillance — a value-based-care metric

— Re-assess prep quality, complete cecal intubation, adequate withdrawal

— Recharacterize any new polyps with size, location, morphology, histology

— Reset the interval based on the new findings, not by adding to the prior plan

— Piecemeal EMR ≥20 mm: 6-month scar inspection → if clear, 1-year exam → then 3 years

— >10 adenomas at one exam: 1-year follow-up with genetic counseling concurrently

— HGD or large advanced adenoma: 3-year follow-up; if clear, can extend

— Patient who missed surveillance window by years: proceed with colonoscopy promptly; do not "skip ahead"

— Reinforce screening rationale and shared decision making about stopping age

— Re-verify family history (new sibling/parent CRC diagnoses change risk)

— Discuss results, next interval, and red-flag symptoms in plain language

— Endoscopy report should explicitly state the recommended surveillance interval

— Path report linked; primary care notified

— Discrepancies between endoscopist recommendation and guidelines should be reconciled — newer guidelines often lengthen intervals (e.g., 1–2 small adenomas now 7–10 years)

CCS pearl: On CCS, when scheduling a surveillance colonoscopy, also order bowel prep instructions and patient education, and advance the clock — abnormal findings on the surveillance exam reset everything.

Step 3 management: A patient hands you a 2014 colonoscopy report saying "repeat in 5 years" for 2 small tubular adenomas. Under current 2020 USMSTF guidelines, this would now be 7–10 years. Apply current recommendations and reset.

Tracking surveillance intervals across the care team:

What to do at the follow-up colonoscopy:

Special follow-up scenarios:

Counseling at follow-up:

Documentation requirements:

Ethical, Legal, and Patient Safety Considerations

— Risks of sedation, bleeding (1–2%, higher with polypectomy), perforation (0.1–1%), missed lesions

— Alternatives: CT colonography (less sensitive for flat/serrated lesions), FIT (screening only, not surveillance)

— Capacity assessment; in cognitively impaired patients, involve surrogate

— Communication failure between endoscopist, pathologist, and primary care is the #1 cause of missed surveillance and interval cancers

— Ensure closed-loop communication: pathology result reaches the ordering clinician AND the patient, with documented next steps

— Lost-to-follow-up patients with prior advanced adenomas are a known liability — systems should generate active recall

— Adverse events (perforation, post-procedure death) reportable to institutional QA; some states mandate reporting of serious procedural adverse events

— Genetic findings (e.g., Lynch) trigger duty to recommend family notification; clinicians cannot directly contact relatives without patient consent

— In patients >75 or with limited life expectancy, document the conversation about benefits vs harms — paternalistic continuation or abrupt discontinuation without discussion is a quality problem

— Surveillance adherence is lower in uninsured/underinsured and minority populations

— Step 3 may ask about navigation programs, patient navigators, and insurance coverage of surveillance colonoscopy (ACA covers screening; surveillance after polypectomy may still incur cost-sharing — counsel patients)

Board pearl: A 62-year-old who had a 15-mm tubulovillous adenoma removed in 2021 and never received the pathology result calls 4 years later. The system failed — the right answer is schedule colonoscopy now, disclose the delay to the patient (transparent error disclosure), and address the system gap.

Step 3 management: Always close the loop: endoscopist → pathologist → primary care → patient. Missing any handoff is the boards' favorite latent safety failure.

Informed consent for surveillance colonoscopy must include:

Transitions of care — high-yield Step 3 safety issue:

Mandatory and recommended reporting:

Shared decision making for stopping surveillance:

Health equity:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: The most commonly missed answer is recognizing serrated lesions as equivalent to adenomas for surveillance — SSLs are not "hyperplastic-ish," they are precancerous and follow nearly identical interval rules.

Step 3 management: Memorize the table from Chunk 6 — it generates 80% of the surveillance-interval questions you'll see.

Advanced adenoma definition: ≥10 mm OR villous component OR high-grade dysplasia → 3-year interval

Hyperplastic polyps <10 mm rectosigmoid: no risk, 10-year interval

Sessile serrated lesion ≥10 mm or with dysplasia, or TSA: 3-year interval

>10 adenomas at one exam: 1-year + genetics referral

Piecemeal EMR of ≥20 mm lesion: 6-month scar check

Inadequate prep: repeat within 1 year (sooner if poor)

Incomplete polypectomy or specimen not retrieved: treat as adenoma; consider repeat

Family history of CRC in 1 FDR <60 or 2 FDRs: screening every 5 years starting at 40 or 10 years before youngest case

Lynch syndrome: colonoscopy q1–2y starting at 20–25

FAP: annual sigmoidoscopy from 10–15

Serrated polyposis syndrome (WHO): ≥5 serrated lesions proximal to rectum (≥2 ≥10 mm), or ≥20 serrated lesions any size throughout colon → 1-year intervals

IBD dysplasia surveillance: start 8–10 years after symptom onset, immediately if PSC

Stop surveillance when life expectancy <10 years or harms exceed benefits

Adenoma detection rate (ADR): ≥25% overall (≥30% men, ≥20% women) — every 1% ADR increase reduces interval cancer by ~3%

Bowel prep quality: Boston Bowel Prep Scale ≥6 total, each segment ≥2

Withdrawal time: ≥6 minutes minimum

Cold snare is now preferred for nonpedunculated polyps <10 mm

CT colonography is an alternative screening modality, not a surveillance tool after advanced polypectomy

FIT/stool DNA: screening only, not surveillance

T1 cancer with high-risk features: surgical resection, not surveillance

Board Question Stem Patterns

— Stem: "55-year-old has colonoscopy showing 2 tubular adenomas, 6 mm and 8 mm, with low-grade dysplasia. Complete resection. When is next colonoscopy?"

— Answer: 7–10 years (some sources still say 5; current USMSTF 2020 says 7–10)

— Stem: "12-mm tubulovillous adenoma with high-grade dysplasia, completely resected en bloc."

— Answer: 3 years

— Stem: "25-mm sessile adenoma resected piecemeal, all visible tissue removed."

— Answer: 6 months for scar evaluation

— Stem: "Bowel prep was poor, only 1 small polyp identified."

— Answer: Repeat colonoscopy within 1 year, regardless of findings

— Stem: "Two 7-mm sessile serrated lesions, no dysplasia, in the ascending colon, completely resected."

— Answer: 5–10 years (1–2 SSLs <10 mm)

— Stem: "30 adenomatous polyps throughout the colon in a 40-year-old."

— Answer: Refer for genetic testing (APC/MUTYH), plan polyposis-syndrome management

— Stem: "Patient with hematochezia 2 years after polypectomy, surveillance due in 1 year."

— Answer: Diagnostic colonoscopy now, not wait

— Stem: "Pathology result never reached primary care; patient missed surveillance."

— Answer: Schedule now + disclose error + improve system

— Stem: "78-year-old with multiple comorbidities and prior small adenomas."

— Answer: Consider stopping surveillance based on life expectancy

Board pearl: When the stem mixes multiple features (e.g., 4 adenomas including one 11-mm villous with HGD), apply the shortest applicable interval — here, 3 years wins.

Step 3 management: Read for prep quality, completeness of resection, and histology in every polyp stem — those three data points produce the answer 95% of the time.

Pattern 1 — Straight histology recall:

Pattern 2 — Advanced adenoma:

Pattern 3 — Piecemeal EMR:

Pattern 4 — Inadequate prep:

Pattern 5 — Serrated lesion:

Pattern 6 — Polyposis recognition:

Pattern 7 — Symptomatic patient (trap):

Pattern 8 — Quality/safety:

Pattern 9 — Elderly:

One-Line Recap

Post-polypectomy surveillance interval is dictated by the highest-risk feature on the index colonoscopy — number, size, histology (villous, HGD, or serrated with dysplasia), and completeness of resection — applied to a high-quality exam, with shortest interval winning when multiple features coexist.

— 1–2 small tubular adenomas, LGD → 7–10 years

— 3–4 small adenomas → 3–5 years

— 5–10 small adenomas, or any adenoma ≥10 mm, or villous, or HGD → 3 years

— >10 adenomas → 1 year + genetics

— Piecemeal EMR ≥20 mm → 6 months

— Hyperplastic polyps <10 mm rectosigmoid → 10 years

— SSL <10 mm, 1–2 lesions, no dysplasia → 5–10 years

— SSL ≥10 mm or with dysplasia, or TSA → 3 years

— Serrated polyposis syndrome → 1 year

— Inadequate prep → repeat within 1 year

— Treating SSLs like hyperplastic polyps (they're not)

— Continuing surveillance in patients with <10-year life expectancy without shared decision making

— Defaulting to "3 years" after every polypectomy without checking quality of resection and prep

— Closed-loop communication of pathology results

— Active EHR recall for surveillance due dates

— Lifestyle counseling and family history re-verification at every visit

Board pearl: Master the USMSTF 2020 table once, and you will own this topic on Step 3.

Anchor numbers to memorize:

Three traps to avoid on Step 3:

Three system-level wins:

Final clinical instinct: When in doubt between two intervals on a Step 3 stem, pick the shorter, higher-risk option — guidelines err on the side of catching advanced neoplasia, and exam writers favor the safer answer when features stack.